[The effect of the coronary dilator lidoflazine on myocardial adenosine metabolism in ischemia and anoxia].
D000241:Adenosine / Q000378:metabolism*; D000244:Adenosine Diphosphate / Q000378:metabolism; D000249:Adenosine Monophosphate / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D002463:Cell Membrane Permeability / Q000187:drug effects; D003331:Coronary Vessels; D004285:Dogs; D006321:Heart / Q000187:drug effects; D007042:Hypoxanthines / Q000378:metabolism; D000860:Hypoxia; D007288:Inosine / Q000378:metabolism; D007511:Ischemia; D007773:Lactates / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism*; D010725:Phosphocreatine / Q000378:metabolism; D010879:Piperazines / Q000494:pharmacology*; D014665:Vasodilator Agents
D007042:Hypoxanthines; D007773:Lactates; D010879:Piperazines; D014665:Vasodilator Agents; D010725:Phosphocreatine; D000249:Adenosine Monophosphate; D007288:Inosine; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D000241:Adenosine
Einfluss des Koronardilators Lidoflazin auf den Adenosinstoffwechsel des Myokards während Ischämie und Anoxie.